tiprankstipranks
Autolus enters non-exclusive license agreement with Cabaletta
The Fly

Autolus enters non-exclusive license agreement with Cabaletta

Autolus Therapeutics (AUTL) announces that it has entered into a non-exclusive license agreement with Cabaletta Bio (CABA). The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety switch into a cell therapy program for the treatment of autoimmune disease, with an option for Cabaletta to incorporate the safety switch in up to four additional cell therapy programs. "We are delighted to partner with Cabaletta and to expand the use of our safety switches in autoimmune disease," said Dr. Martin Pule, Chief Scientific Officer of Autolus. "Safety switches are critical to the future of our field of advanced cell therapies. They allow us to develop approaches that are designed to significantly improve patient outcomes, whilst at the same time potentially reducing the risk of adverse side effects from the treatment." Under the terms of the agreement, Autolus will receive an upfront payment for non-exclusive access to the RQR8 safety switch for use in Cabaletta’s CD19-CAR T cell therapy program for the treatment of autoimmune disease, with the potential for near term option exercise fees and development and regulatory milestone payments. In addition, Autolus is entitled to receive royalties on net sales of all Cabaletta cell therapy products that incorporate the RQR8 safety switch.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AUTL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles